Glico
4-6-5 Utajima, Nishi-Yodogawa-ku, Osaka, 555-8502, Japan
Overview
Ezaki Glico Co. is a food company headquartered in Osaka, Japan. It has 11 business locations and 23 group companies in Japan, and 12 subsidiaries in nine countries. Ezaki Glico operates a total of 19 plants and has 5,210 employees all over the world. Since the launch in 1922 of the nutritious and fortified Glico caramel in its distinctive red box, the business activities of Ezaki Glico have adhered to the corporate philosophy of "Enhancing Public Health Through Food." Upon the 70th anniversary of Ezaki Glico in 1992, this same spirit and dedication have been incorporated into the revised corporate philosophy of "A Wholesome Life in the Best of Taste." Glico caramel – the company's first product – incorporates the innovative creativeness of Mr. Riichi Ezaki, the company's founder. From the beginning, all personnel working for the company have been dedicated to further enhancing people's health and quality of life. This has led to the expansion of business lines beyond confectionery to include ice cream products, processed foods, desserts, milk products, baby formula, food ingredients, and ingredients for cosmetic and health products.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- Food and Beverage
- Food Processing
- Manufacturing
Investment portfolio
- Viome Life Sciences
Participated · Series C · Nov 2021
Viome Life Sciences, based in Bellevue, WA and led by Founder and CEO Naveen Jain, focuses on longevity and preventative healthcare. The company leverages AI and algorithms to analyze gene expression data from over 600,000 samples to power at-home tests and personalized recommendations. Its product lineup includes custom-formulated supplements unique to each individual, personalized biotic blends for gut health, and oral biotic lozenges for oral microbiome health. Viome intends to deploy new capital toward research and development and retail expansion. Financially, it has raised a total of $175M to date after closing an $86.5M Series C. Investors in the most recent round include Khosla Ventures, Bold Capital, WRG Ventures and others. Viome Life Sciences is a Bellevue, WA-based systems biology company that uses biological data to help individuals improve their health. The company positions itself around systems-biology approaches to personalized health. Public reporting emphasizes its aim to translate biological insights into health-improvement offerings. Financially, Viome has been an active fundraiser, most recently securing a $54M pre-Series C convertible round. This follows a $56M Series B announced in November 2019 and brings total funding to date to over $125M. Returning and new investor participation has supported its continued operations and product development efforts.
Team
Riichi Ezaki
Founder & CEO